Is long-term bisphosphonate administration associated with significantly increased circulating parathormone levels in patients with multiple myeloma?

被引：1
作者：
Cook, G [1 ]
机构：
[1] St James Univ Hosp, BMT Programme, Leeds Blood & Marrow Transplantat Ctr, Leeds LS9 7TF, W Yorkshire, England
来源：
EUROPEAN JOURNAL OF ENDOCRINOLOGY | 2003年 / 149卷 / 05期
关键词：
D O I：
10.1530/eje.0.1490467
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：467 / 468
页数：2
相关论文
共 7 条
[1]   Safety and efficacy of bisphosphonates beyond 24 months in cancer patients [J].
Ali, SM ;
Esteva, FJ ;
Hortobagyi, G ;
Harvey, H ;
Seaman, J ;
Knight, R ;
Costa, L ;
Lipton, A .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (14) :3434-3437
[2]  
Kanis John A., 2000, Cancer, V88, P3022, DOI 10.1002/1097-0142(20000615)88:12+<3022::AID-CNCR19>3.0.CO
[3]  
2-R
[4]   Markers of bone resorption in patients treated with pamidronate [J].
Lipton, A ;
Demers, L ;
Curley, E ;
Chinchilli, V ;
Gaydos, L ;
Hortobagyi, G ;
Theriault, R ;
Clemens, D ;
Costa, L ;
Seaman, J ;
Knight, R .
EUROPEAN JOURNAL OF CANCER, 1998, 34 (13) :2021-2026
[5]  
McCloskey EV, 1998, BRIT J HAEMATOL, V100, P317
[6]  
Raje N, 2000, BLOOD, V96, P381
[7]  
Smith A, 2001, BRIT J HAEMATOL, V115, P522
1